公开(公告)号：US20180147165A1

公开(公告)日：2018-05-31

申请号：US15879600

申请日：2018-01-25

Applicant: SOL-GEL TECHNOLOGIES LTD.

Inventor： Hanan Sertchook ,  Ofer Toledano ,  Haim Bar-Simantov

IPC: A61K31/165 ,  A61K31/327 ,  A61K47/10 ,  A61K9/50 ,  A61K9/107 ,  A61K9/00 ,  A61K47/14 ,  A61K31/7052 ,  A61K31/704 ,  A61K31/192 ,  A61K31/7056 ,  A61K9/06

CPC classification number: A61K31/165 ,  A61K9/00 ,  A61K9/0014 ,  A61K9/06 ,  A61K9/1075 ,  A61K9/501 ,  A61K31/192 ,  A61K31/327 ,  A61K31/704 ,  A61K31/7052 ,  A61K31/7056 ,  A61K47/10 ,  A61K47/14 ,  A61K2300/00

Abstract: The present invention relates to pharmaceutical compositions for topical use (including also dermatological compositions), for treating skin conditions and afflictions, such as rosacea and symptoms and conditions associated there from.

公开(公告)号：US12156946B2

公开(公告)日：2024-12-03

申请号：US17016528

申请日：2020-09-10

Applicant: SOL-GEL TECHNOLOGIES LTD.

Inventor： Ofer Toledano ,  Haim Bar-Simantov ,  Nissim Bilman ,  Leora Shapiro ,  Raed Abu-Reziq ,  Hanan Sertchook

IPC: A61K9/50 ,  A01N25/26 ,  A01N53/00 ,  A61K8/11 ,  A61K8/25 ,  A61K8/38 ,  A61K8/67 ,  A61Q19/00 ,  B01J13/02 ,  B01J13/22 ,  C09C3/06

Abstract: The invention relates to a process for coating a solid, water-insoluble particulate matter, with a metal oxide comprising: (a) contacting the solid, water-insoluble particulate matter with an ionic additive and an aqueous medium to obtain a dispersion of said particulate matter having positive charges on its surface; (b) subjecting the particulate matter to a coating procedure comprising precipitating a metal oxide salt onto the surface of the particulate matter to form a metal oxide layer thereon to thereby obtain particulate matter coated by a metal oxide coating layer; (c) repeating step (b) at least 4 more times; and (d) aging said coating layer. The invention further relates to particles comprising a particulate matter coated by a metal oxide layer, to a use of the particles for topical administration, and to a method for preventing, reducing, or eliminating pests at a locus, using the particles.

公开(公告)号：US11986456B2

公开(公告)日：2024-05-21

申请号：US18076444

申请日：2022-12-07

Applicant: Sol-Gel Technologies Ltd.

Inventor： Moshe Arkin ,  Karine Neimann ,  Ofer Toledano

IPC: A61K31/327 ,  A61K9/00 ,  A61K9/06 ,  A61K9/10 ,  A61K9/107 ,  A61K9/50 ,  A61P17/00 ,  A61P17/10

CPC classification number: A61K31/327 ,  A61K9/0014 ,  A61K9/06 ,  A61K9/10 ,  A61K9/107 ,  A61K9/50 ,  A61P17/00 ,  A61P17/10

Abstract: A regimen is described for the therapeutic treatment of rosacea. The regimen includes topically applying a pharmaceutical composition to the skin of a subject in need of said treatment. The pharmaceutical composition includes from about 2.5% to about 10% benzoyl peroxide as the only active ingredient, and a pharmaceutically acceptable carrier or excipient. The regimen achieves, in a group of such subjects, a primary measure of success of at least about 9%, at least about 25%, at least about 40%, or at least about 47%, after application of said pharmaceutical composition once daily for at least about 2 weeks, at least about 4 weeks, at least about 8 weeks, or at least about 12 weeks, respectively.

公开(公告)号：US11877997B2

公开(公告)日：2024-01-23

申请号：US17156941

申请日：2021-01-25

Applicant: Sol-Gel Technologies Ltd.

Inventor： Ofer Toledano ,  Ofra Levy-Hacham ,  Ori Nov ,  Vered Ram

IPC: A61K31/327 ,  A61P17/10 ,  A61K9/00 ,  A61K9/06 ,  A61K9/107 ,  A61P17/00 ,  A61K9/50 ,  A61K9/10

CPC classification number: A61K31/327 ,  A61K9/0014 ,  A61K9/06 ,  A61K9/10 ,  A61K9/107 ,  A61K9/50 ,  A61P17/00 ,  A61P17/10

Abstract: A regimen is described for providing early onset of action in the therapeutic treatment of rosacea including topically applying a pharmaceutical composition to the skin of a subject in need of said treatment. The pharmaceutical composition includes about 1% to about 10% benzoyl peroxide as the only active ingredient, and a pharmaceutically acceptable carrier or excipient. The pharmaceutical composition is applied once daily for a period of at least about 2, 4, 8 or 12 weeks. Based on early onset of action, a primary measure of success is at least about 9%, primary measure of success being defined as a 2-grade improvement in IGA of clear or almost clear; and a secondary measure of success is at least about 40%, secondary measure of success being defined as mean inflammatory lesion count percent reduction from baseline, after at least about 2 weeks of treatment.

公开(公告)号：US11541026B2

公开(公告)日：2023-01-03

申请号：US17541847

申请日：2021-12-03

Applicant: Sol-Gel Technologies Ltd.

Inventor： Moshe Arkin ,  Karine Neimann ,  Ofer Toledano

IPC: A61K31/327 ,  A61P17/10 ,  A61K9/00 ,  A61K9/06 ,  A61K9/107 ,  A61P17/00 ,  A61K9/50 ,  A61K9/10

Abstract: A regimen is described for the therapeutic treatment of rosacea. The regimen includes topically applying a pharmaceutical composition to the skin of a subject in need of said treatment. The pharmaceutical composition includes from about 2.5% to about 10% benzoyl peroxide as the only active ingredient, and a pharmaceutically acceptable carrier or excipient. The regimen achieves, in a group of such subjects, a primary measure of success of at least about 9%, at least about 25%, at least about 40%, or at least about 47%, after application of said pharmaceutical composition once daily for at least about 2 weeks, at least about 4 weeks, at least about 8 weeks, or at least about 12 weeks, respectively.

公开(公告)号：US11071878B2

公开(公告)日：2021-07-27

申请号：US15924331

申请日：2018-03-19

Applicant: SOL-GEL TECHNOLOGIES LTD.

Inventor： Ofer Toledano ,  Haim Bar-Simantov ,  Hanan Sertchook ,  Sharon Fireman-Shoresh ,  Dorit Marco

IPC: A61Q19/00 ,  B01J13/14 ,  A61K9/51 ,  A61K9/00 ,  A61K8/67 ,  A61K8/38 ,  A61K8/26 ,  A61K8/25 ,  A61K8/11 ,  A61K9/06 ,  A61K9/50 ,  B01J13/18 ,  F28D20/02 ,  A61K9/10 ,  A61K47/38 ,  A61K47/32

Abstract: The present invention provides core-stabilized microcapsules, wherein said core comprises at least one active agent encapsulated within an inorganic oxide shell, processes for their preparations, comparisons comprising them and uses thereof.

公开(公告)号：US20210113511A1

公开(公告)日：2021-04-22

申请号：US17137883

申请日：2020-12-30

Applicant: Sol-Gel Technologies Ltd.

Inventor： Ofer Toledano ,  Ofra Levy-Hacham ,  Rinat Mizrahi

IPC: A61K31/203 ,  A61K9/00 ,  A61P17/10 ,  A61K9/50 ,  A61K31/327

Abstract: The present application is directed to regimens, methods of treatment, and compositions for the treatment of acne in a subject suffering therefrom.

公开(公告)号：US10945987B2

公开(公告)日：2021-03-16

申请号：US16794734

申请日：2020-02-19

Applicant: Sol-Gel Technologies Ltd.

Inventor： Ofer Toledano ,  Ofra Levy-Hacham ,  Ori Nov ,  Vered Ram

IPC: A61K31/327 ,  A61P17/10 ,  A61K9/00 ,  A61K9/06 ,  A61K9/107 ,  A61P17/00 ,  A61K9/50 ,  A61K9/10

Abstract: A regimen is described for providing early onset of action in the therapeutic treatment of rosacea including topically applying a pharmaceutical composition to the skin of a subject in need of said treatment. The pharmaceutical composition includes about 1% to about 10% benzoyl peroxide as the only active ingredient, and a pharmaceutically acceptable carrier or excipient. The pharmaceutical composition is applied once daily for a period of at least about 2, 4, 8 or 12 weeks. Based on early onset of action, a primary measure of success is at least about 9%, primary measure of success being defined as a 2-grade improvement in IGA of clear or almost clear; and a secondary measure of success is at least about 40%, secondary measure of success being defined as mean inflammatory lesion count percent reduction from baseline, after at least about 2 weeks of treatment.

公开(公告)号：US12295935B2

公开(公告)日：2025-05-13

申请号：US18123702

申请日：2023-03-20

Applicant: Sol-Gel Technologies Ltd.

Inventor： Ofer Toledano ,  Ori Nov

IPC: A61K31/327 ,  A61K9/00 ,  A61K9/06 ,  A61K9/10 ,  A61K9/107 ,  A61K9/50 ,  A61P17/00 ,  A61P17/10

Abstract: A regimen and a pharmaceutical composition for the treatment of a skin condition and/or skin affliction are described. The regimen includes topically applying to the skin of a subject in need of such treatment a pharmaceutical composition comprising about 2.5% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and a pharmaceutically acceptable carrier or excipient.

公开(公告)号：US12070629B2

公开(公告)日：2024-08-27

申请号：US17340334

申请日：2021-06-07

Applicant: Sol-Gel Technologies Ltd.

Inventor： Ofer Toledano ,  Haim Bar-Simantov ,  Hanan Sertchook ,  Sharon Fireman-Shoresh ,  Dorit Marco

IPC: A61Q19/00 ,  A61K8/11 ,  A61K8/25 ,  A61K8/26 ,  A61K8/38 ,  A61K8/67 ,  A61K9/00 ,  A61K9/06 ,  A61K9/10 ,  A61K9/50 ,  A61K9/51 ,  B01J13/14 ,  B01J13/18 ,  F28D20/02 ,  A61K47/32 ,  A61K47/38

CPC classification number: A61Q19/00 ,  A61K8/11 ,  A61K8/25 ,  A61K8/26 ,  A61K8/38 ,  A61K8/671 ,  A61K9/0014 ,  A61K9/06 ,  A61K9/10 ,  A61K9/501 ,  A61K9/5115 ,  A61K9/5192 ,  B01J13/14 ,  B01J13/18 ,  F28D20/023 ,  A61K9/5026 ,  A61K47/32 ,  A61K47/38 ,  A61K2800/412

Abstract: The present invention provides core-stabilized microcapsules, wherein said core comprises at least one active agent encapsulated within an inorganic oxide shell, processes for their preparations, comparisons comprising them and uses thereof.